Unión Europea - islandés - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Æxlishemjandi lyf - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - tafla - 50 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 1 g

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 500 mg

Unión Europea - islandés - EMA (European Medicines Agency)

instituto grifols s.a. - mönnum eðlilegt að notkun - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - Ónæmiskerfið sera og mótefni, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Unión Europea - islandés - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - lyf til veikindi öndunarvegi sjúkdómum, - fasenra er ætlað sem bæta á viðhald meðferð í fullorðinn sjúklinga með alvarlega eósínófíl asma ekki nægilega stjórnað þrátt fyrir hár-skammt andað krefur plús langverkandi beta örvum.

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - simvastatinum inn - filmuhúðuð tafla - 40 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg

Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg